A close look at monoclonal antibodies for managing canine OA painJanuary 15, 2026As veterinary care continues to shift toward preventive medicine and lifelong wellness, there is growing momentum around improving earlier detection and more consistent pain management. Among the emerging therapeutic options is a new class of biologics: monoclonal antibodies (mAbs).
SPONSORED CONTENTTake Control With ProHeart 12 (moxidectin)One dose offers year-long protection with a single injection, putting compliance in your hands. + Learn more
Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
